Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2,187.32% | -95.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2,187.32% | -95.25% | |||
| Cost of Revenue | 3.05% | -93.81% | |||
| Gross Profit | 8,057.02% | -155.07% | |||
| SG&A Expenses | -19.45% | -44.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.72% | -42.67% | |||
| Operating Income | 114.55% | -25.65% | |||
| Income Before Tax | 112.86% | 25.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 112.86% | 25.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 112.86% | 25.09% | |||
| EBIT | 114.55% | -25.65% | |||
| EBITDA | 115.34% | -25.56% | |||
| EPS Basic | 112.88% | 25.16% | |||
| Normalized Basic EPS | 112.81% | -17.79% | |||
| EPS Diluted | 112.88% | 25.16% | |||
| Normalized Diluted EPS | 112.81% | -17.79% | |||
| Average Basic Shares Outstanding | 0.34% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.41% | 0.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||